The size of the Autoimmune Monoclonal Antibodies Market in the Middle East and Africa is expected to reach USD 1642.99 million by 2027 from USD 1183.55 million in 2022, growing at a CAGR of 6.78% during the forecast period.
The rising prevalence of cancer and other chronic diseases, rising regulatory approvals and therapy launches, and growing research collaborations for the development of a robust drug pipeline are the major factors driving the growth of the Middle East and Africa autoimmune monoclonal antibodies market over the forecast period. The participants of the market are investing heavily in research and development to create treatments with fewer negative effects for patients. These strategies are the players' last resort in order to compete in the market for MEA anti-CD20 monoclonal antibodies.
However, the majority of these medications come with adverse effects, which leads to limited patient adherence. Due to these adverse effects, as well as numerous research and advances in the field of targeted therapies, such as anti-CD20 mABs, the number of targeted therapies, such as anti-CD20 mABs, has expanded over time.
This research report on the MEA Autoimmune Monoclonal Antibodies Market has been segmented and sub-segmented into the following categories
By Source:
By Application:
By End-User:
By Country:
During the forecast period, the MEA market is expected to register a healthy growth rate. Countries such as the United Arab Emirates and Kuwait have proven to be highly beneficial as target therapies in the treatment of cancer indications. These medications specifically target the CD20 antigen on cancer cells, which is not possible with standard treatments. The regional expansion of the MEA anti-CD20 monoclonal antibodies (mABs) market is projected to be boosted by increasing inventions in this field and several affirmative clinical trials.
KEY MARKET PLAYERS:
Companies such as GlaxoSmithKline plc (U.K.), AstraZeneca plc (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb (U.S.), Johnson & Johnson (U.S.), Innovent Biologics, Inc. (China), Takeda Pharmaceutical Company Ltd. (Japan), Amgen Inc. (U.S.), Biogen Inc. (U.S.), and UCB Company (Belgium) are playing a leading role in the MEA Autoimmune Monoclonal Antibodies Market.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Source
5.1.1 Murine
5.1.2 Chimeric
5.1.3 Humanized
5.1.4 Human
5.2 By Application
5.2.1 Systemic Lupus Erythematosus
5.2.2 Rheumatoid Arthritis
5.2.3 Multiple Sclerosis
5.2.4 Transplant Rejection/Graft Versus Host Disease
5.2.5 Others
5.3 End User
5.3.1 Hospitals/Clinics
5.3.2 Research Institute
5.3.3 Diagnostic Laboratories
6. Geographical Analysis
6.1 Middle East & Africa
6.1.1 Introduction
6.1.2 Middle-East
6.1.3 Africa
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
7.5 Key Trends in Monoclonal Antibodies Development
7.5.1 Targeted Therapies
7.6 Promising Monoclonal Antibodies in Pipeline
7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Monoclonal Antibodies
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 GlaxoSmithKline plc (U.K.)
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.2 AstraZeneca plc (U.K.)
9.3 F. Hoffmann-La Roche Ltd. (Switzerland)
9.4 Bristol-Myers Squibb (U.S.)
9.5 Johnson & Johnson (U.S.)
9.6 Innovent Biologics, Inc. (China)
9.7 Takeda Pharmaceutical Company Ltd. (Japan)
9.8 Amgen Inc. (U.S.)
9.6 Innovent Biologics, Inc. (China)
9.10 UCB Company (Belgium)
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
